BridgeBio Pharma (NASDAQ:BBIO) Releases Earnings Results, Misses Estimates By $0.20 EPS

BridgeBio Pharma (NASDAQ:BBIO) announced its quarterly earnings data on Monday. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.20), FiscalAI reports. The firm had revenue of $243.68 million during the quarter, compared to the consensus estimate of $220.91 million.

Here are the key takeaways from BridgeBio Pharma’s conference call:

• Attruby net product revenue reached $222.4 million, up $150.9 million year over year and more than $35 million sequentially. Growth was led by treatment-naive, first-line patients, while the company expects additional support from kidney-protection data and real-world evidence.
• BridgeBio said Attruby is positioned to benefit from the failed CARDIO-TTRansform combination-therapy study, which it believes reinforces stabilizers as the first-line treatment backbone. Management expects clinical differentiation, including early outcomes and renal benefits, to support further share gains over the next 12–18 months.
• All three major pipeline programs advanced into regulatory review: BBP-418 for LGMD2I received priority review with a November 27, 2026 PDUFA date, encaleret for ADH1 received priority review with a May 8, 2027 target date, and infigratinib’s achondroplasia NDA was submitted. The company is building commercial infrastructure for potential launches over the next 12–18 months.
• Operating expenses rose to $335.7 million as BridgeBio invested in Attruby and preparations for three launches, though the operating loss improved 20% year over year to $107.1 million. Following a $1 billion preferred-equity financing, management expects operating results to remain roughly stable for several quarters before moving toward breakeven and cash generation in 2027.

BridgeBio Pharma Price Performance

BridgeBio Pharma stock traded up $0.19 during mid-day trading on Monday, hitting $84.67. 2,940,042 shares of the company’s stock traded hands, compared to its average volume of 3,004,735. The firm has a 50 day simple moving average of $75.69 and a two-hundred day simple moving average of $72.98. BridgeBio Pharma has a fifty-two week low of $46.28 and a fifty-two week high of $93.42. The stock has a market cap of $16.55 billion, a price-to-earnings ratio of -22.64 and a beta of 0.96.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on BBIO shares. Canaccord Genuity Group started coverage on BridgeBio Pharma in a report on Wednesday, June 3rd. They set a “buy” rating and a $104.00 target price on the stock. HC Wainwright raised their price target on BridgeBio Pharma from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Mizuho lowered their price target on BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 16th. Morgan Stanley upped their price objective on BridgeBio Pharma from $94.00 to $98.00 and gave the stock an “overweight” rating in a research note on Thursday, May 28th. Finally, Truist Financial increased their price objective on BridgeBio Pharma from $95.00 to $102.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Nineteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $97.33.

Insider Buying and Selling

In other news, Director Andrea Ellis sold 17,167 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $84.00, for a total transaction of $1,442,028.00. Following the completion of the sale, the director owned 22,579 shares in the company, valued at approximately $1,896,636. This trade represents a 43.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jennifer E. Cook sold 148,589 shares of the stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $88.54, for a total transaction of $13,156,070.06. Following the completion of the transaction, the director directly owned 8,383 shares in the company, valued at approximately $742,230.82. This represents a 94.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 392,117 shares of company stock valued at $29,934,700. 14.23% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BridgeBio Pharma

Institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. boosted its holdings in BridgeBio Pharma by 23.0% in the 4th quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock valued at $369,547,000 after purchasing an additional 902,648 shares during the period. Mackenzie Financial Corp raised its position in shares of BridgeBio Pharma by 8.9% in the fourth quarter. Mackenzie Financial Corp now owns 54,495 shares of the company’s stock valued at $4,105,000 after buying an additional 4,448 shares in the last quarter. XTX Topco Ltd raised its position in shares of BridgeBio Pharma by 162.4% in the fourth quarter. XTX Topco Ltd now owns 13,169 shares of the company’s stock valued at $1,007,000 after buying an additional 8,150 shares in the last quarter. VARCOV Co. acquired a new stake in shares of BridgeBio Pharma in the fourth quarter valued at approximately $340,000. Finally, Voloridge Investment Management LLC boosted its stake in shares of BridgeBio Pharma by 377.4% in the fourth quarter. Voloridge Investment Management LLC now owns 638,883 shares of the company’s stock valued at $48,868,000 after buying an additional 505,051 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.